Abstract:Background: Excessive endogenous glucose production is a major contributing factor for fasting hyperglycemia in diabetes. Results: FoxO6 deficiency attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice. Conclusion: FoxO6 plays a significant role in regulating gluconeogenesis in the liver. Significance: FoxO6 is a potential therapeutic target for improving glucose metabolism in diabetes. Excessive endogenous glucose production contributes to fasting hyperglycemia in diabetes. FoxO6 is a distinct member of the FoxO subfamily. To elucidate the role of FoxO6 in hepatic gluconeogenesis and assess its contribution to the pathogenesis of fasting hyperglycemia in diabetes, we generated FoxO6 knock-out (FoxO6-KO) mice followed by determining the effect of FoxO6 loss-of-function on hepatic gluconeogenesis under physiological and pathological conditions. FoxO6 depletion attenuated hepatic gluconeogenesis and lowered fasting glycemia in FoxO6-KO mice. FoxO6-deficient primary hepatocytes were associated with reduced capacities to produce glucose in response to glucagon. When fed a high fat diet, FoxO6-KO mice exhibited significantly enhanced glucose tolerance and reduced blood glucose levels accompanied by improved insulin sensitivity. These effects correlated with attenuated hepatic gluconeogenesis in FoxO6-KO mice. In contrast, wild-type littermates developed fat-induced glucose intolerance with a concomitant induction of fasting hyperinsulinemia and hyperglycemia. Furthermore, FoxO6-KO mice displayed significantly diminished macrophage infiltration into liver and adipose tissues, correlating with the reduction of macrophage expression of C-C chemokine receptor 2 (CCR2), a factor that is critical for regulating macrophage recruitment in peripheral tissues. Our data indicate that FoxO6 depletion protected against diet-induced glucose intolerance and insulin resistance by attenuating hepatic gluconeogenesis and curbing macrophage infiltration in liver and adipose tissues in mice.

FoxO1 Links Hepatic Insulin Action to Endoplasmic Reticulum Stress

Aberrant Forkhead Box O1 Function is Associated with Impaired Hepatic Metabolism

FoxO6 Integrates Insulin Signaling with Gluconeogenesis in the Liver.

Foxo1 Mediates Insulin Action on Apoc-Iii and Triglyceride Metabolism

FoxO1 Plays an Important Role in Regulating Β-Cell Compensation for Insulin Resistance in Male Mice.

A Mutant Allele Encoding DNA Binding–Deficient FoxO1 Differentially Regulates Hepatic Glucose and Lipid Metabolism

FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes

Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis

Targeting FoxO1 for hypertriglyceridemia.

An insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice

1574-P: FoxO1 Links Insulin Resistance to Hepatic Inflammation and Catalyzes the Evolution of Benign Steatosis to Nonalcoholic Steatohepatitis

Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1

Phosphorylation of Forkhead Protein FoxO1 at S253 Regulates Glucose Homeostasis in Mice.

FoxO integration of insulin signaling with glucose and lipid metabolism.

Endoplasmic reticulum stress induces hepatic steatosis through interaction between PPARα and FoxO6 in vivo and in vitro

Reciprocal Regulation of Hepatic TGF-β1 and Foxo1 Controls Gluconeogenesis and Energy Expenditure

Foxo1 Mediates the Autocrine Effect of Endothelin-1 on Endothelial Cell Survival

Nuclear Transcription Factor Foxo1 and Glucose,lipid Metabolism

Forkhead Box O6 (foxo6) Depletion Attenuates Hepatic Gluconeogenesis and Protects Against Fat-induced Glucose Disorder in Mice.

A Novel Mechanism by Foxo1 Phosphorylation Mediates Glucagon Signaling in Control of Glucose Homeostasis

Regulation of FoxOs Transcription Factors on Body Metabolism